Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: A prospective study

Lupus

Volumn 17, Issue 8, 2008, Pages 744-751

  Traitanon, O ^a   Avihingsanon, Yingyos ^a   Kittikovit, V ^a   Townamchai, N ^a   Kanjanabuch, T ^a   Praditpornsilpa, K ^a   Wongchinasri, J ^b   Tungsanga, K ^a   Eiam Ong, S ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

Cyclophosphamide; Enteric coated mycophenolate sodium; Lupus nephritis; Mycophenolate

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; ALOPECIA; AMENORRHEA; ANEMIA; ARTICLE; CHICKENPOX; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENTERIC COATED TABLET; ENTERITIS; FEMALE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; KIDNEY BIOPSY; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NAUSEA; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; REPEATED DRUG DOSE; SEPTICEMIA; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KIDNEY; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED;

EID: 49749110774     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308090991     Document Type: Article

References (30)

1. Moroni, G, Quaglini, S, Maccario, M, Banfi, G, Ponticelli, C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-2053.
2. Ioannidis, JP, Boki, KA, Katsorida, ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264.
3. Mok, CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum 2006; 36: 71-81.
4. Cortés-Hernández, J, Ordi-Ros, J, Labrador, M, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287-296.
5. Contreras, G, Pardo, V, Leclercq, B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
6. Chan, TM, Li, FK, Tang, CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
7. Hu, W, Liu, Z, Chen, H, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 2002; 115: 705-709.
8. Ginzler, EM, Dooley, MA, Aranow, C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
9. Dooley, MA, Cosio, FG, Nachman, PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-839.
10. Kingdon, EJ, McLean, AG, Psimenou, E, et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606-611.
11. Karim, MY, Alba, P, Cuadrado, MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 2002; 41: 876-882.
12. Salvadori, M, Holzer, H, de Mattos, A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-236.
13. Sumethkul, V, Na-Bangchang, K, Kantachuvesiri, S, Jirasiritham, S. Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. Transplant Proc 2005; 37: 861-863.
14. Arns, W, Breuer, S, Choudhury, S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005; 19: 199-206.
15. Ong, LM, Hooi, LS, Lim, TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005; 10: 504-510.
16. Calvo, N, Sanchez-Fructuoso, AI, Conesa, J, Moreno, A, Barrientos, A. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transplant Proc 2006; 38: 2396-2397.
17. Grossman, JM, Kalunian, KC. Definition, classification, activity and damage indices. In: Wallace, DJ, Hahn, BH, (eds), Systemic lupus erythematosus. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 19-31.
18. Appel, GB, Radhakrishnan, J, D'Agati, VD. Secondary glomerular disease. In: Brenner, BM, (ed), The kidney. Philadelphia: Saunders; 2004. p. 1381-1481.
19. Pollak, VE, Pirani, CL, Dujovne, I, Dillard, MG. The clinical course of lupus nephritis: relationship to the renal histologic findings. Perspect Nephrol Hypertens 1973; 1: 1167-1181.
20. Austin, HA, Muenz, LR, Joyce, KM, Antonovych, TT, Balow, JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
21. Levey, AS, Greene, T, Kusek, JW, Beck, GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.
22. Boumpas, DT, Balow, JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7: 622-629.
23. Burchardi, C, Schlöndorff, D. Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide. Nat Clin Pract Nephrol 2006; 2: 314-315.
24. Austin, HA, Klippel, JH, Balow, JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
25. Mok, CC, Lai, KN. Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 2002; 40: 447-457.
26. Kapitsinou, PP, Boletis, JN, Skopouli, FN, Boki, KA, Moutsopoulos, HM. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology 2004; 43: 377-380.
27. Zabaleta-Lanz, M, Vargas-Arenas, RE, Tapanes, F, Daboin, I, Atahualpa Pinto, J, Bianco, NE. Silent nephritis in systemic lupus erythematosus. Lupus 2003; 12: 26-30.
28. Leehey, DJ, Katz, AI, Azaran, AH, Aronson, AJ, Spargo, BH. Silent diffuse lupus nephritis: long-term follow-up. Am J Kidney Dis 1982; 2: 188-196.
29. Moroni, G, Pasquali, S, Quaglini, S, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999; 34: 530-539.
30. Chan, TM, Tse, KC, Tang, CS, Mok, MY, Li, FK.; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.